BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Boston Scientific Corporation (BSX) Wins Patent Infringement Case Against Johnson & Johnson (JNJ) In The Netherlands


10/19/2005 5:08:52 PM

NATICK, Mass., June 9 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today announced that a Dutch court has ruled that Cordis Europa N.V. ("Cordis"), a subsidiary of Johnson & Johnson , infringes a Boston Scientific balloon catheter patent. The following catheter products were found to infringe: the CYPHER(R) RAPTOR(TM), the CYPHER SELECT(TM), the Bx VELOCITY(R) RAPTOR(TM), the Bx SONIC(TM), the U-Pass, and the AQUA T3(TM). The court's decision gives Boston Scientific the right to damages and to an injunction against Cordis' manufacturing, using, or selling the infringing catheters in the Netherlands.

"We are very pleased with the decision. It confirms our belief that Boston Scientific is at the forefront of innovation and has fundamental intellectual property in the treatment of coronary artery disease," said Paul LaViolette, Boston Scientific's Chief Operating Officer. "We are hopeful that it will provide an opportunity for a fair and reasonable settlement of the numerous disputes between our two companies."

Boston Scientific is a worldwide developer, manufacturer, and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.

This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with litigation and other factors described in the Company's filings with the Securities and Exchange Commission.

CONTACT: Milan Kofol 508-650-8569 Investor Relations Boston Scientific Corporation Paul Donovan 508-650-8541 Media Relations Boston Scientific Corporation

Boston Scientific Corporation

CONTACT: Milan Kofol, +1-508-650-8569, Investor Relations, or PaulDonovan, +1-508-650-8541, Media Relations, both of Boston ScientificCorporation



Read at BioSpace.com
Read at Market Watch

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES